MX2021003119A - Anticuerpos anti-klrg1. - Google Patents
Anticuerpos anti-klrg1.Info
- Publication number
- MX2021003119A MX2021003119A MX2021003119A MX2021003119A MX2021003119A MX 2021003119 A MX2021003119 A MX 2021003119A MX 2021003119 A MX2021003119 A MX 2021003119A MX 2021003119 A MX2021003119 A MX 2021003119A MX 2021003119 A MX2021003119 A MX 2021003119A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- klrg1
- antigen
- binding fragments
- klrg1 antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La invención se refiere a anticuerpos, o fragmentos de unión al antígeno de estos, que se unen específicamente al receptor G1 lectinoide de linfocitos citolíticos (KLRG1). Dichos anticuerpos, o fragmentos de unión al antígeno de estos, son útiles para diversos fines terapéuticos o de diagnóstico, incluido el tratamiento de cánceres y para aumentar la eficacia de las vacunas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862732329P | 2018-09-17 | 2018-09-17 | |
PCT/US2019/050110 WO2020060781A1 (en) | 2018-09-17 | 2019-09-06 | Anti-klrg1 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021003119A true MX2021003119A (es) | 2021-05-14 |
Family
ID=69887899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021003119A MX2021003119A (es) | 2018-09-17 | 2019-09-06 | Anticuerpos anti-klrg1. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210347899A1 (es) |
EP (1) | EP3852779A4 (es) |
JP (1) | JP2022501065A (es) |
KR (1) | KR20210060477A (es) |
CN (1) | CN112752580A (es) |
AU (1) | AU2019344524A1 (es) |
BR (1) | BR112021004553A2 (es) |
CA (1) | CA3113069A1 (es) |
EA (1) | EA202190647A1 (es) |
IL (1) | IL281594A (es) |
MX (1) | MX2021003119A (es) |
SG (1) | SG11202102114UA (es) |
WO (1) | WO2020060781A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022056289A1 (en) * | 2020-09-11 | 2022-03-17 | National Jewish Health | Methods and compositions for treating respiratory diseases or conditions related to innate lymphoid cells |
IL307241A (en) | 2021-03-26 | 2023-11-01 | Abcuro Inc | Antibodies against KLRG1 |
WO2022204529A1 (en) | 2021-03-26 | 2022-09-29 | Abcuro, Inc. | Anti-klrg1 antibodies |
WO2024072872A2 (en) * | 2022-09-27 | 2024-04-04 | The Brigham And Women's Hospital, Inc. | Klrg1 signalling therapy for infectious disease |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3045637A1 (en) * | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
ES2624835T3 (es) * | 2009-08-06 | 2017-07-17 | Immunas Pharma, Inc. | Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos |
JP6097690B2 (ja) * | 2010-09-02 | 2017-03-15 | ヴァクシネックス, インコーポレイテッド | 抗cxcl13抗体およびそれを用いる方法 |
JPWO2012176765A1 (ja) * | 2011-06-24 | 2015-02-23 | 株式会社ペルセウスプロテオミクス | 抗ヒトp−カドへリン(cdh3)遺伝子組み換え抗体 |
CN106456766B (zh) * | 2014-03-19 | 2020-03-10 | 台湾基督长老教会马偕医疗财团法人马偕纪念医院 | 抗免疫原性糖肽的抗体、包含其的组合物及其用途 |
CA3026182A1 (en) * | 2016-06-03 | 2017-12-07 | Steven Greenberg | Klrg1 signaling therapy |
AU2017326003A1 (en) * | 2016-09-16 | 2019-04-11 | Children's Medical Center Corporation | KLRG1 depletion therapy |
-
2019
- 2019-09-06 KR KR1020217008068A patent/KR20210060477A/ko unknown
- 2019-09-06 SG SG11202102114UA patent/SG11202102114UA/en unknown
- 2019-09-06 EP EP19862063.5A patent/EP3852779A4/en active Pending
- 2019-09-06 CA CA3113069A patent/CA3113069A1/en active Pending
- 2019-09-06 WO PCT/US2019/050110 patent/WO2020060781A1/en unknown
- 2019-09-06 MX MX2021003119A patent/MX2021003119A/es unknown
- 2019-09-06 JP JP2021539334A patent/JP2022501065A/ja active Pending
- 2019-09-06 EA EA202190647A patent/EA202190647A1/ru unknown
- 2019-09-06 US US17/285,793 patent/US20210347899A1/en active Pending
- 2019-09-06 BR BR112021004553-8A patent/BR112021004553A2/pt unknown
- 2019-09-06 CN CN201980060735.4A patent/CN112752580A/zh active Pending
- 2019-09-06 AU AU2019344524A patent/AU2019344524A1/en active Pending
-
2021
- 2021-03-17 IL IL281594A patent/IL281594A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020060781A1 (en) | 2020-03-26 |
IL281594A (en) | 2021-05-31 |
EP3852779A4 (en) | 2022-06-08 |
AU2019344524A1 (en) | 2021-03-25 |
BR112021004553A2 (pt) | 2021-06-08 |
SG11202102114UA (en) | 2021-04-29 |
EA202190647A1 (ru) | 2021-09-09 |
JP2022501065A (ja) | 2022-01-06 |
KR20210060477A (ko) | 2021-05-26 |
US20210347899A1 (en) | 2021-11-11 |
CN112752580A (zh) | 2021-05-04 |
CA3113069A1 (en) | 2020-03-26 |
EP3852779A1 (en) | 2021-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021003119A (es) | Anticuerpos anti-klrg1. | |
PH12020552010A1 (en) | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof | |
NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
MX2022004072A (es) | Anticuerpos de factor xi y metodos de uso. | |
EA201791050A1 (ru) | Конъюгаты антител и лекарственных средств | |
MX2022014914A (es) | Compuestos de interaccion con glicanos y metodos de uso. | |
MY200162A (en) | Anti-gitr antibodies and uses thereof | |
PH12018502275A1 (en) | Interferon beta antibodies and uses thereof | |
MX2021008958A (es) | Proteínas de unión a antígeno del receptor gamma anti-il2. | |
MX2020008122A (es) | Anticuerpos anti-pd-1. | |
EA202090372A1 (ru) | Универсальные соединения авт и их применение | |
EA201792561A1 (ru) | Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения | |
MX2022011972A (es) | Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas. | |
ZA202202363B (en) | Antibodies against ilt2 and use thereof | |
EA202090791A1 (ru) | Агонистические антитела против cd40 | |
MX2019009498A (es) | Anticuerpos mimeticos de fgf21 y usos de los mismos. | |
EA201990988A1 (ru) | Антитела против chikv и пути их применения | |
CO2019002550A2 (es) | Anticuerpos anti-gm-csf y usos de los mismos | |
MX2021007589A (es) | Anticuerpos anti il-36 y procedimientos de uso de estos. | |
MX2022004194A (es) | Anticuerpos contra el receptor de virus de la polio (pvr) y usos de los mismos. | |
MX2021010766A (es) | Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos. | |
MX2023001776A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
MX2023011102A (es) | Anticuerpos anti-klrg1. | |
EA202092121A1 (ru) | Антитела против cd73 и их применения | |
EA202092151A1 (ru) | Антитела |